Videos

Choi describes existing evidence on statin use in patients with liver disease and reviews his new research about their potential utility in PBC.

An interview conducted at Maui Derm 2026 highlights a presentation by Raj Chovatiya, MD, PhD, on managing atopic dermatitis and itch in 2026.

A retrospective study found an independent association between increased pain episodes in sickle cell disease and the cold in light of increasingly extreme weather.

In this segment of a Liver Lineup episode, experts discuss where the new US Dietary Guidelines miss the mark for alcohol recommendations.

Friedmann describes his research exploring the benefits of mobile telemedicine for HCV infection among persons who inject drugs in rural areas.

Ruff explains his prespecified analysis of the phase 2b AZALEA-TIMI 71 trial, highlighting abelacimab’s efficacy and durability compared to rivaroxaban.

Hovanesian breaks down the process by which Yuvezzi received FDA approval and discusses the prescription and application of the new drug.

The 2025 KDIGO guidelines guide mechanism-driven therapy in IgA nephropathy, highlighting targeted interventions across the 4-hit disease cascade.

This segment of Liszewski’s interview at Maui Derm Hawaii 2026 highlights additional takeaways for clinicians regarding the treatment of contact dermatitis.

The DROP-FPF Phase 3b trial will use automated HRCT biomarkers to assess whether early treatment with nerandomilast can slow disease progression before lung function declines.

Russman highlights asundexian’s efficacy in patients following a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

2025 KDIGO guidelines reshape IgA nephropathy care with earlier biopsy, tighter proteinuria targets, and personalized treatment strategies.

In the final segment, experts discuss how to navigate traditional or cultural foods with patients in the absence of their inclusion in the guidelines.

In part 7 of the discussion, experts reflect on access issues regarding foods recommended in the guidelines.

Part 6 of the discussion takes a closer look at added sugar recommendations from the guidelines and scenarios where individualization may be needed.

In part 5 of the discussion, the panel examines gaps within the pediatric sections of the updated dietary guidelines.

In part 4 of the discussion, experts review notable omissions and oversights in the guidelines, including fiber, whole grains, and plant-based foods.

In part 3 of this discussion, experts break down saturated fat recommendations and why visuals in the guidelines may cause confusion.

In part 2 of the discussion, experts discuss recommendations around protein intake, including controversy and misconceptions.

In the opening segment of this special report, a trio of experts discuss what's new in the 2025-2030 Dietary Guidelines.

Delay discounting links to residual depression symptoms but does not predict relapse after stopping antidepressant treatment in patients with remitted MDD.

In this Maui Derm Hawaii 2026 interview, key takeaways on contact dermatitis treatment strategies are highlighted by Liszewski.

Catch up on hepatic FDA news, expert insights on PBC and MASH developments, & more.

Longitudinal data identify aromatic lactate–producing bifidobacteria and the metabolite 4-hydroxy-phenyllactate as key factors in early immune tolerance.

This interview at Maui Derm 2026 highlights notable takeaways regarding psoriasis treatment strategies and emerging therapies.

Despite usability concerns cited by the FDA, investigators say dibutepinephrine’s needle-free, portable design could still address gaps in real-world epinephrine use.

Anouti describes clinical uncertainties regarding signs of cholestatic liver disease, like jaundice, in patients with skin of color, and how this may impact transplant outcomes.

Catch up with major trial results, key FDA approvals, and more.